eXoZymes’ cell‑free biomanufacturing platform was run at pilot scale by Cayman Chemical, which reported results consistent with or exceeding prior in‑house runs: a 100‑L pilot produced more than 500 grams of N‑trans‑caffeoyltyramine at 99.6% purity with high conversion and reproducibility. Cayman advanced the protocol and reported robustness under pilot conditions, including pH variation and precipitation challenges. eXoZymes framed the external run as validation of platform transferability and scale potential, reducing execution risk for enzyme‑based processes. The experiment highlights growing interest in cell‑free production to accelerate biomanufacturing and reduce downstream purification burdens for small‑molecule and specialty outputs.